Inactive Instrument

Novartis AG Stock Xetra

Equities

NOT

CH0012005267

Pharmaceuticals

Sales 2024 * 48.79B 45.58B Sales 2025 * 50.63B 47.29B Capitalization 199B 186B
Net income 2024 * 10.23B 9.56B Net income 2025 * 11.85B 11.07B EV / Sales 2024 * 4.33 x
Net Debt 2024 * 12.19B 11.38B Net Debt 2025 * 10.9B 10.18B EV / Sales 2025 * 4.15 x
P/E ratio 2024 *
19.5 x
P/E ratio 2025 *
16.7 x
Employees 76,057
Yield 2024 *
3.69%
Yield 2025 *
3.83%
Free-Float 81.95%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 04-12-31
Director of Finance/CFO 59 02-12-31
Chief Tech/Sci/R&D Officer 62 22-05-15
Members of the board TitleAgeSince
Director/Board Member 62 12-12-31
Director/Board Member 65 20-02-27
Chairman 68 12-12-31
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company